Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian .
ORPHAZYME A/SJune 28, 2021 GMT
Orphazyme A/S Company Registration No. 32266355
Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced 24-month interim results of an open-label extension (OLE) trial, providing efficacy and safety data for its investigational treatment arimoclomol in Niemann-Pick disease type C (NPC) for up to 36 months. The data are featured in a presentation as part of the Parseghian Scientific Conference for Niemann-Pick disease type C Research.
United-states
Denmark
Copenhagen
Køavn
Switzerland
Chicago
Illinois
Christophe-bourdon
Maria-wilkens
Marc-patterson
Molly-carey-poarch
Drug-administration